Gland Pharma Limited has informed the Exchange regarding 'BRSR Report for the FY 2025'.
GLAND · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Gland Pharma submitted its Business Responsibility and Sustainability Report (BRSR) for FY 2024-25 to BSE and NSE, as required under SEBI's listing regulations. The company is a pharmaceutical firm focused on complex injectables, with 100% of turnover from generic formulations and 88.97% from exports across 60 countries. It operates 7 national and 4 international plants with 4,313 permanent employees. Reported turnover stands at ₹41,161.49 crore and net worth at ₹97,551.02 crore, with Fosun Pharma holding a 51.83% stake. No fines, penalties, bribery, or corruption cases were reported during the year. The company has board diversity of 25% (2 of 8 directors are women), holds ISO 14001, ISO 45001, ISO 9001, and WHO GMP certifications, and has switched from furnace oil to piped natural gas at facilities to reduce emissions.
This is a routine regulatory ESG disclosure and is unlikely to move the stock. However, it highlights strong export dependence (~89%) and improving employee retention (turnover dropped from 23% to 14%), which signals operational stability. Investors can view the shift to cleaner fuels and certifications as a positive ESG indicator for long-term sustainability.